Secukinumab is a medication given as an injection under the skin. It belongs to a class of medicines called biologics, which are made from living cells. Secukinumab works by blocking a protein in the body that can cause inflammation and damage to the skin, joints, and other parts of the body. In this trial, patients who have already taken secukinumab in a previous study continue receiving the medicine so researchers can watch how safe it is when used for a longer time. The study looks for any side effects or serious problems that might happen while the patients keep using the drug.

Psoriatic Arthritis – a type of arthritis that occurs in people with psoriasis, causing joint pain, swelling, and stiffness; it can affect the fingers, toes, and spine, and may lead to progressive joint changes over time.
Ankylosing Spondylitis – a long‑term inflammation of the spine and sacroiliac joints that causes back pain and stiffness; with time the vertebrae can become fused, reducing flexibility of the spine.
Non‑radiographic Axial Spondyloarthritis – an early form of axial spondyloarthritis where inflammation causes back pain and stiffness but does not yet show on X‑ray; it may later develop visible changes in the spine.
Severe Chronic Plaque Psoriasis – a skin condition marked by thick, red, scaly patches that cover large areas of the body; the plaques can become increasingly thick and cause itching or discomfort.
Moderate to severe Chronic Plaque Psoriasis – a skin disorder with red, scaly plaques affecting a moderate to large part of the body; the lesions may expand and become more noticeable over time.
Juvenile idiopathic arthritis – a group of arthritis conditions that start before age 16, causing joint swelling, pain, and limited movement; it can involve one or many joints and may persist as the child grows.